Acute Myeloid Leukemia
Conditions
Interventions
group A:The first course: secondary prevention mode
The second course: treatment mode
group B:The first course: treatment mode
The second course: secondary prevention mode
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
16 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Age range 14-60 years, gender unlimited; 2.AML (except M3, M7 and M6); 3.Cytological CR was achieved in the early induction therapy; 4.At least 2 courses of MID/HID-Ara-C containing chemotherapy are planned, and the type and dose of chemotherapy drugs must be the same for both courses; 5.No other platelet growth factors were used during the study period.
Exclusion criteria
Exclusion criteria: 1.AML with a history of prodromal MDS or chronic leukemia, MPN sudden change; 2.The PLT count before rhTPO is greater than 300G/L; 3.Past thromboembolic diseases; 4.Combined with severe infection before treatment; 5.Allergy or intolerance to rhTPO; 6.Merge other tumors; 7.The researcher believes that there are any other circumstances that may prevent the subject from completing the study or bring obvious risks to the subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of Grade III of CIT;Duration of Grade IV of CIT; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of different grades of CIT;Duration from the first time when PLT was below 20G/L to the time when it recovered to 20G/L, 30G/L, and above 50G/L;Time of CIT occurrence;Number of platelet transfusions;The total amount of rhTPO per treatment course;Safety; | — |
Countries
China
Contacts
Public ContactWang Yadan
Wuhan Union Hospital
Outcome results
None listed